Journal of Clinical Oncology, Vol 16, 237-245, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group

DM Green, NE Breslow, JB Beckwith, JZ Finklestein, PE Grundy, PR Thomas, T Kim, SJ Shochat, GM Haase, ML Ritchey, PP Kelalis and GJ D'Angio
Department of Pediatrics, Roswell Park Cancer Institute, University at Buffalo, State University of New York, 14623, USA. green@SC3101.med.buffalo.edu

PURPOSE: The National Wilms' Tumor Study (NWTS)-4 was designed to evaluate the efficacy, toxicity, and cost of administration of different regimens for the treatment of Wilms' tumor (WT). PATIENTS AND METHODS: Between August 6, 1986 and September 1, 1994, 1,687 previously untreated children less than 16 years of age with stages I to II/favorable histology (FH) or stage I/anaplastic histology WT (low- risk [LR] group) or stages III to IV/FH WT or stages I to IV/clear cell sarcoma of the kidney (high-risk [HR] group) were randomized to treatment that included vincristine and either divided-dose (standard [STD]) courses (5 days) or single-dose (pulse-intensive [PI]) treatment with dactinomycin. HR patients also received either STD courses (3 days) or PI treatment with doxorubicin. RESULTS: The 2-year relapse- free survival (RFS) rates for LR patients were 91.3% for 544 randomized to treatment with PI and 91.4% for 556 randomized to treatment with STD chemotherapy (P = .988). The 2-year RFS rates for HR patients were 87.3% for 299 randomized to treatment with PI and 90.0% for 288 randomized to treatment with STD chemotherapy (P = .865). CONCLUSION: We conclude that patients treated with PI combination chemotherapy for LR or HR WT or clear cell sarcoma of the kidney have equivalent 2-year RFS to those treated with STD regimens. PI drug administration is recommended as the new standard based on demonstrated efficacy, greater administered dose-intensity, less severe hematologic toxicity, and the requirement for fewer physician and hospital encounters.

This article has been cited by other articles:

				J. Jiang and Z. Haibo Additive hazard regression with auxiliary covariates Biometrika, June 1, 2007; 94(2): 359 - 369. [Abstract] [Full Text] [PDF]

				J. S. Dome, C. A. Cotton, E. J. Perlman, N. E. Breslow, J. A. Kalapurakal, M. L. Ritchey, P. E. Grundy, M. Malogolowkin, J. B. Beckwith, R. C. Shamberger, et al. Treatment of Anaplastic Histology Wilms' Tumor: Results From the Fifth National Wilms' Tumor Study J. Clin. Oncol., May 20, 2006; 24(15): 2352 - 2358. [Abstract] [Full Text] [PDF]

				B. B. Phillips, R. R Digmann, and M G. Beck Hepatitis Associated with Low-Dose Venlafaxine for Postmenopausal Vasomotor Symptoms Ann. Pharmacother., February 1, 2006; 40(2): 323 - 327. [Abstract] [Full Text] [PDF]

				S. N. Whitney, A. M. Ethier, E. Fruge, S. Berg, L. B. McCullough, and M. Hockenberry Decision Making in Pediatric Oncology: Who Should Take the Lead? The Decisional Priority in Pediatric Oncology Model J. Clin. Oncol., January 1, 2006; 24(1): 160 - 165. [Abstract] [Full Text] [PDF]

				M. L. Metzger and J. S. Dome Current Therapy for Wilms' Tumor Oncologist, November 1, 2005; 10(10): 815 - 826. [Abstract] [Full Text] [PDF]

				G. E. Tomlinson, N. E. Breslow, J. Dome, K. A. Guthrie, P. Norkool, S. Li, P. R.M. Thomas, E. Perlman, J. B. Beckwith, G. J. D'Angio, et al. Rhabdoid Tumor of the Kidney in The National Wilms' Tumor Study: Age at Diagnosis As a Prognostic Factor J. Clin. Oncol., October 20, 2005; 23(30): 7641 - 7645. [Abstract] [Full Text] [PDF]

				P. E. Grundy, N. E. Breslow, S. Li, E. Perlman, J. B. Beckwith, M. L. Ritchey, R. C. Shamberger, G. M. Haase, G. J. D'Angio, M. Donaldson, et al. Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group J. Clin. Oncol., October 10, 2005; 23(29): 7312 - 7321. [Abstract] [Full Text] [PDF]

				A. D. Campbell, S. L. Cohn, M. Reynolds, R. Seshadri, E. Morgan, G. Geissler, A. Rademaker, M. Marymount, J. Kalapurakal, P. R. Haut, et al. Treatment of Relapsed Wilms' Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Children's Memorial Hospital J. Clin. Oncol., July 15, 2004; 22(14): 2885 - 2890. [Abstract] [Full Text] [PDF]

				N. L. Seibel, S. Li, N. E. Breslow, J. B. Beckwith, D. M. Green, G. M. Haase, M. L. Ritchey, P. R.M. Thomas, P. E. Grundy, J. Z. Finklestein, et al. Effect of Duration of Treatment on Treatment Outcome for Patients With Clear-Cell Sarcoma of the Kidney: A Report From the National Wilms' Tumor Study Group J. Clin. Oncol., February 1, 2004; 22(3): 468 - 473. [Abstract] [Full Text] [PDF]

				A. Revel and J. Schenker Ovarian tissue banking for cancer patients: is ovarian cortex cryopreservation presently justified? Hum. Reprod., January 1, 2004; 19(1): 14 - 19. [Abstract] [Full Text] [PDF]

				N. E. Breslow, R. Norris, P. A. Norkool, T. Kang, J. B. Beckwith, E. J. Perlman, M. L. Ritchey, D. M. Green, and K. E. Nichols Characteristics and Outcomes of Children With the Wilms Tumor-Aniridia Syndrome: A Report From the National Wilms Tumor Study Group J. Clin. Oncol., December 15, 2003; 21(24): 4579 - 4585. [Abstract] [Full Text] [PDF]

				K Pritchard-Jones Controversies and advances in the management of Wilms' tumour Arch. Dis. Child., September 1, 2002; 87(3): 241 - 244. [Abstract] [Full Text] [PDF]

				D. M. Green, Y. A. Grigoriev, B. Nan, J. R. Takashima, P. A. Norkool, G. J. D'Angio, and N. E. Breslow Congestive Heart Failure After Treatment for Wilms' Tumor: A Report From the National Wilms' Tumor Study Group J. Clin. Oncol., April 1, 2001; 19(7): 1926 - 1934. [Abstract] [Full Text] [PDF]

				A. Eggert, M. A. Grotzer, N. Ikegaki, H. Zhao, A. Cnaan, G. M. Brodeur, and A. E. Evans Expression of the Neurotrophin Receptor TrkB Is Associated With Unfavorable Outcome in Wilms' Tumor J. Clin. Oncol., February 1, 2001; 19(3): 689 - 696. [Abstract] [Full Text] [PDF]

				M. F. Tournade, C. Com-Nougue, J. de Kraker, R. Ludwig, A. Rey, J. M.B. Burgers, B. Sandstedt, J. Godzinski, M. Carli, R. Potter, et al. Optimal Duration of Preoperative Therapy in Unilateral and Nonmetastatic Wilms' Tumor in Children Older Than 6 Months: Results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study J. Clin. Oncol., January 15, 2001; 19(2): 488 - 500. [Abstract] [Full Text] [PDF]

				N. S. Adzick and M. L. Nance Pediatric Surgery- Second of Two Parts N. Engl. J. Med., June 8, 2000; 342(23): 1726 - 1732. [Full Text] [PDF]

				M. H. Porteus, P. Narkool, D. Neuberg, K. Guthrie, N. Breslow, D. M. Green, and L. Diller Characteristics and Outcome of Children With Beckwith-Wiedemann Syndrome and Wilms' Tumor: A Report From the National Wilms Tumor Study Group J. Clin. Oncol., May 10, 2000; 18(10): 2026 - 2031. [Abstract] [Full Text] [PDF]